Pathogenesis-based therapies in ichthyoses

Autor: Lai-Cheong, JE, Elias, PM, Paller, AS

Publikováno v: Lai-Cheong, JE; Elias, PM; & Paller, AS. (2013). Pathogenesis-based therapies in ichthyoses. Dermatologic Therapy, 26(1), 46-54. doi: 10.1111/j.1529-8019.2012.01528.x. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/1qb746zt

During the past 20 years, tremendous progress has been made in our understanding of the molecular basis of many genetic skin conditions. The translation of these laboratory findings into effective therapies for affected individuals has been slow, how

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::443129d0702d24e1c675a489c34f710d
http://www.escholarship.org/uc/item/1qb746zt

Inhibition of Wnt Signaling in Colon Cancer Cells via an Oral Drug that Facilitates TNIK Degradation.

Autor: Zhou K; Luye Pharma Boston R&D, Woburn, Massachusetts., Cheong JE; Silicon Therapeutics, Boston, Massachusetts., Krishnaji ST; Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts., Ghalali A; Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts., Fu H; Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts., Sui L; Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts., Alix-Panabières C; The University of Montpellier, Montpellier, France., Cayrefourcq L; The University of Montpellier, Montpellier, France., Bielenberg D; Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts., Sun L; Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts., Zetter B; Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2023 Jan 03; Vol. 22 (1), pp. 25-36.

Topical Application of a Mast Cell Stabilizer Improves Impaired Diabetic Wound Healing.

Autor: Tellechea A; Joslin-Beth Israel Deaconess Foot Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Bai S; Center for Drug Discovery and Translational Research, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Dangwal S; Joslin-Beth Israel Deaconess Foot Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Institute for Translational and Therapeutics Strategies, Hannover Medical School, Hannover, Germany., Theocharidis G; Joslin-Beth Israel Deaconess Foot Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Nagai M; Center for Drug Discovery and Translational Research, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Koerner S; Center for Drug Discovery and Translational Research, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Cheong JE; Center for Drug Discovery and Translational Research, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Bhasin S; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Genomics, Proteomics, Bioinformatics and Systems Biology Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Shih TY; John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Cambridge, Massachusetts, USA., Zheng Y; Joslin-Beth Israel Deaconess Foot Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Zhao W; Joslin-Beth Israel Deaconess Foot Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Zhang C; Joslin-Beth Israel Deaconess Foot Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Li X; Joslin-Beth Israel Deaconess Foot Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Kounas K; Joslin-Beth Israel Deaconess Foot Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA., Panagiotidou S; Laboratory of Immunopharmacology and Drug, Discovery Department of Immunology Tufts University School of Medicine, Boston, Massachusetts, USA., Theoharides T; Laboratory of Immunopharmacology and Drug, Discovery Department of Immunology Tufts University School of Medicine, Boston, Massachusetts, USA., Mooney D; John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Cambridge, Massachusetts, USA., Bhasin M; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Genomics, Proteomics, Bioinformatics and Systems Biology Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: mbhasin@bidmc.harvard.edu., Sun L; Center for Drug Discovery and Translational Research, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: lsun1@bidmc.harvard.edu., Veves A; Joslin-Beth Israel Deaconess Foot Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: aveves@bidmc.harvard.edu.

Publikováno v: The Journal of investigative dermatology [J Invest Dermatol] 2020 Apr; Vol. 140 (4), pp. 901-911.e11. Date of Electronic Publication: 2019 Sep 27.

A patent review of IDO1 inhibitors for cancer.

Autor: Cheong JE; a Center for Drug Discovery and Translational Research and Department of Surgery, Beth Israel Deaconess Medical Center , Harvard Medical School , Boston , MA , USA., Ekkati A; a Center for Drug Discovery and Translational Research and Department of Surgery, Beth Israel Deaconess Medical Center , Harvard Medical School , Boston , MA , USA., Sun L; a Center for Drug Discovery and Translational Research and Department of Surgery, Beth Israel Deaconess Medical Center , Harvard Medical School , Boston , MA , USA.

Publikováno v: Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2018 Apr; Vol. 28 (4), pp. 317-330. Date of Electronic Publication: 2018 Feb 23.

Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.

Autor: Cheong JE; Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Zaffagni M; Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA., Chung I; Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia., Xu Y; Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA., Wang Y; Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Jernigan FE; Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Zetter BR; Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA. Electronic address: bruce.zetter@childrens.harvard.edu., Sun L; Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address: lsun1@bidmc.harvard.edu.

Publikováno v: European journal of medicinal chemistry [Eur J Med Chem] 2018 Jan 20; Vol. 144, pp. 372-385. Date of Electronic Publication: 2017 Dec 14.